Tags: Diabetes | oramed | insulin | oral

Oral Insulin Successful in Trial

Thursday, 30 Jan 2014 08:25 AM

Oramed, an Israeli developer of oral drug delivery systems, said on Thursday a mid-stage trial for its oral insulin capsule for the treatment of Type 2 diabetes met all primary and secondary endpoints.
During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with Type 2 diabetes took part in an in-patient setting for one week.
Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated.

"We are extremely pleased with the results, which give a solid validation for Oramed's platform technology in general and our oral insulin programme in particular," said Nadav Kidron, Oramed's chief executive.

Kidron said the company is planning a Phase 2b study later in 2014 and will initiate a Phase 2a FDA study for Type 1 diabetes in the near term.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved